1. Home
  2. RVPHW vs FLX Comparison

RVPHW vs FLX Comparison

Compare RVPHW & FLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPHW
  • FLX
  • Stock Information
  • Founded
  • RVPHW 2018
  • FLX 2013
  • Country
  • RVPHW United States
  • FLX China
  • Employees
  • RVPHW 14
  • FLX N/A
  • Industry
  • RVPHW Biotechnology: Pharmaceutical Preparations
  • FLX
  • Sector
  • RVPHW Health Care
  • FLX
  • Exchange
  • RVPHW Nasdaq
  • FLX NYSE
  • Market Cap
  • RVPHW N/A
  • FLX N/A
  • IPO Year
  • RVPHW N/A
  • FLX 2024
  • Fundamental
  • Price
  • RVPHW $0.03
  • FLX $3.17
  • Analyst Decision
  • RVPHW
  • FLX
  • Analyst Count
  • RVPHW 0
  • FLX 0
  • Target Price
  • RVPHW N/A
  • FLX N/A
  • AVG Volume (30 Days)
  • RVPHW 22.4K
  • FLX 60.9K
  • Earning Date
  • RVPHW 03-14-2025
  • FLX 08-27-2025
  • Dividend Yield
  • RVPHW N/A
  • FLX N/A
  • EPS Growth
  • RVPHW N/A
  • FLX N/A
  • EPS
  • RVPHW N/A
  • FLX N/A
  • Revenue
  • RVPHW N/A
  • FLX $595,490,250.00
  • Revenue This Year
  • RVPHW N/A
  • FLX N/A
  • Revenue Next Year
  • RVPHW N/A
  • FLX N/A
  • P/E Ratio
  • RVPHW N/A
  • FLX N/A
  • Revenue Growth
  • RVPHW N/A
  • FLX N/A
  • 52 Week Low
  • RVPHW $0.13
  • FLX $2.01
  • 52 Week High
  • RVPHW $0.15
  • FLX $21.95
  • Technical
  • Relative Strength Index (RSI)
  • RVPHW N/A
  • FLX N/A
  • Support Level
  • RVPHW N/A
  • FLX N/A
  • Resistance Level
  • RVPHW N/A
  • FLX N/A
  • Average True Range (ATR)
  • RVPHW 0.00
  • FLX 0.00
  • MACD
  • RVPHW 0.00
  • FLX 0.00
  • Stochastic Oscillator
  • RVPHW 0.00
  • FLX 0.00

About RVPHW Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: